AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33660924
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg/day)
Trial: 35322393
Drug: Vibrating insole
RxNorm normalized name: VIBRATING DEVICE,CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrating insole device (VS) with 22-min daily vibrating sequences at 90% of tactile threshold
Trial: 38502056
Drug: Mirabegron (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (200 mg)
Trial: 34363761
Drug: GARD (genomic-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GARD (genomic-adjusted radiation dose)
Trial: 34363761
Drug: Physical dose
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical dose of radiation
Trial: 34363761
Drug: Sham-GARD (standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-GARD (standard-of-care dose without radiotherapy)
Trial: 33371043
Drug: 9-month all-oral
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-month all-oral bedaquiline-containing regimen
Trial: 34847610
Drug: Lu AG06466
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AG06466 (40 mg)
Trial: 35960174
Drug: Standard technique/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard technique/lidocaine injection
Trial: 35960174
Drug: New device/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New device/lidocaine patch
Trial: 35960174
Drug: New device/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New device/lidocaine injection
Trial: 33663566
Drug: Tight Control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight Control of psoriatic arthritis (TICOPA) trial with a treat to target (T2T) strategy consisting of 4-weekly review and escalation of therapy (single DMARD, combination DMARDs, and then biologics) based on remission criteria.
Trial: 33663566
Drug: T2T approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T2T approach supported when monitoring treatment within the cohort.
Trial: 34978231
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT) intervention for 10 sessions
Trial: 33317579
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal therapy (HFNT)
Trial: 32596788
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of ecological executive skills training (EEST)
Trial: 32035706
Drug: HUU/3+1 (3-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HUU/3+1 (3-dose priming and booster), HUU/3+0 (3-dose priming without booster), HUU/2+1 (2-dose priming and booster).
Trial: 34057299
Drug: Fractionated weekly
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated weekly DCF (D 40 mg/m2, C 35 mg/m², F 1800 mg/m² over 24 h, on days 1 and 8 every 3 weeks)
Trial: 34057299
Drug: Fortnightly DCF
RxNorm normalized name: TRACH TUBE,SZ 4 CUFFLESS SHLY #4-DCFS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortnightly DCF (D 50 mg/m2, C 50 mg/m², F 2000 mg/m² over 48 h every 2 weeks)
Trial: 35779610
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (INCS) for 3 months
Trial: 35779610
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (INCS) for 12 months
Trial: 35015210
Drug: Ulipristal 10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulipristal 10-mg daily
Trial: 35015210
Drug: Combination oral
RxNorm normalized name: PROBIOTIC COMBINATION ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oral contraceptive (COC)
Trial: 35106694
Drug: D‐IUI and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐IUI and D‐IVF treatments in single women (SW)
Trial: 35106694
Drug: D‐IUI and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐IUI and D‐IVF treatments in women in lesbian relationships (WLR)
Trial: 35106694
Drug: D‐IUI treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐IUI treatments
Trial: 35106694
Drug: D‐IVF treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐IVF treatments
Trial: 33693537
Drug: Standard-of-care control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care control (PO-10, rifampicin 10 mg/kg/day)
Trial: 33693537
Drug: Intravenous rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous rifampicin (IV-20, 20 mg/kg/day)
Trial: 33693537
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral rifampicin (PO-35, 35 mg/kg/day)
Trial: 33549194
Drug: Posaconazole (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (300 mg twice on day 1, followed by 300 mg once a day for days 2–84)
Trial: 33549194
Drug: Voriconazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2–84)
Trial: 34488846
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg PZQ at baseline and placebo at 6 months
Trial: 34488846
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg PZQ at baseline and 40 mg/kg PZQ at 6 months
Trial: 34488846
Drug: 80 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/kg PZQ at baseline and placebo at 6 months
Trial: 34488846
Drug: 80 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/kg PZQ at baseline and 80 mg/kg PZQ at 6 months
Trial: 33369355
Drug: CC-486 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (300 mg) once daily for 14 days per 28-day cycle
Trial: 33369355
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 14 days per 28-day cycle
Trial: 35183780
Drug: 0.12% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% CHX solutions
Trial: 32750572
Drug: Daily symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily symptom check-in text messages, plus medication reminder or inspirational quote text
Trial: 35795313
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) 900 mg twice daily for 3 months
Trial: 33721560
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg IV every 3 weeks for 16 cycles or up to 1 year
Trial: 34622679
Drug: DAPT with
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT with cilostazol and clopidogrel or aspirin
Trial: 34622679
Drug: SAPT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAPT with clopidogrel or aspirin
Trial: 32293706
Drug: Pitolisant hydrochloride
RxNorm normalized name: PITOLISANT HYDROCHLORIDE
DrugBank: Pitolisant (DB11642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pitolisant hydrochloride (40 mg)
Trial: 32745891
Drug: Oxytocin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (both doses)
Trial: 37277072
Drug: Dexpramipexole 150
RxNorm normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpramipexole 150 mg BID
Trial: 37277072
Drug: Dexpramipexole 75
RxNorm normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpramipexole 75 mg BID
Trial: 34836388
Drug: Biobran/MGN-3 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biobran/MGN-3 (500 mg/day)
Trial: 33517607
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen treatment (venturi mask/nasal cannula)
Trial: 33264183
Drug: Anti-tumor necrosis
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tumor necrosis factor therapy
Trial: 36288939
Drug: Ciclesonide 400
RxNorm normalized name: Ciclesonide 400 microgram and formoterol fumarate dihydrate 12 microgram and tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 400 µg three times a day for seven days
Trial: 35436957
Drug: Intensive education
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive education program on treatment of tobacco-use disorder
Trial: 33030598
Drug: Supervised aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised aerobic endurance, resistance, and balance exercises twice a week at the hospital plus home-based exercise once a week for 12-24 weeks
Trial: 32362552
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bevacizumab (subgroup with BCVA ≤69 letters)
Trial: 32362552
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab (subgroup with BCVA ≤69 letters)
Trial: 32362552
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bevacizumab (subgroup with BCVA ≥70 letters)
Trial: 32362552
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab (subgroup with BCVA ≥70 letters)
Trial: 33668564
Drug: EGF-containing ointment
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF-containing ointment
Trial: 36154487
Drug: Dramatic narrative
RxNorm normalized name: AMMONIA,AROMATIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dramatic narrative featuring Latina characters countering prevalent myths about COVID-19 vaccines
Trial: 36301511
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine (5 mg/kg second dose)
Trial: 36301511
Drug: Enteral caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral caffeine (5 mg/kg second dose)
Trial: 35565828
Drug: Mg-Teadiola (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-Teadiola (combination of magnesium, vitamins B6, B9, B12, rhodiola, and green tea/L-theanine)
Trial: 35565828
Drug: Mg-Teadiola
RxNorm normalized name: MG 217 Psoriasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-Teadiola
Trial: 38743075
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection (control)
Trial: 32022261
Drug: APG-157 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-157 (100 mg or 200 mg, delivered transorally every hour for 3 hours)
Trial: 34112734
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eosinophils and FENO
Trial: 34483640
Drug: Lowest postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lowest postoperative pre-albumin < 15 mg/dL
Trial: 33050362
Drug: HBOT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOT treatment after exercise in NN conditions (HNN group)
Trial: 33050362
Drug: HBOT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOT treatment after exercise in HH conditions (HHH group)
Trial: 616871163
Drug: Moderate aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate aerobic exercise (at least 30 min per day, 5 times weekly)
Trial: 34340880
Drug: 0.75% citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% citric acid spray
Trial: 34340880
Drug: Cool water
RxNorm normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 15 g in 100 g TOPICAL STICK [Secret Cool Waterlily Invisible]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cool water spray
Trial: 35220330
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) pregabalin (150 to 600 mg/d) once daily for 12 weeks
Trial: 35220330
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) pregabalin (150 to 600 mg/d) twice daily for 12 weeks
Trial: 35220330
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) pregabalin
Trial: 32059724
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living abilities of the PwD
Trial: 34226214
Drug: Enhanced occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced occupational therapy discharge planning intervention (the HOME programme) including pre and postdischarge home visits, goal setting, and occupational therapy in the home.
Trial: 35370039
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of adjuvant doublet chemotherapy (CAPOX)
Trial: 35370039
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of adjuvant doublet chemotherapy
Trial: 33336381
Drug: Bumetanide (diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (diuretic agent)
Trial: 34623899
Drug: Ifosfamide and
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide and doxorubicin chemotherapy plus 55.8 Gy RT (Arm C)
Trial: 35510727
Drug: Epilepsy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epilepsy group using psychiatric drugs
Trial: 35752301
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management with misoprostol (800 μg sublingually)
Trial: 33726819
Drug: Neuromuscular blocking
RxNorm normalized name: Neuromuscular blocking agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blocking agents
Trial: 36414990
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures retained by 4 interforaminal implants (Test)
Trial: 36414990
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures retained by 2 interforaminal implants (Control)
Trial: 32389326
Drug: Contezolid (MRX-I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contezolid (MRX-I) 600 mg BID for 14 days under fed conditions
Trial: 32389326
Drug: Contezolid (MRX-I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contezolid (MRX-I) 800 mg BID for 14 days under fed conditions
Trial: 32389326
Drug: Contezolid (MRX-I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contezolid (MRX-I) 800 mg BID for 7-14 days under fed conditions
Trial: 33896930
Drug: Paclitaxel drug-coated
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel drug-coated balloons (Pantera Lux)
Trial: 34175866
Drug: Closed‐incision negative‐pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed‐incision negative‐pressure therapy (ciNPT)
Trial: 33792788
Drug: Ranibizumab (RBZ)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (RBZ) therapy, 0.5 or 2.0 mg, monthly intravitreal injections for 6 consecutive injections followed by as-needed treatments.
Trial: 33709192
Drug: Dexmedetomidine-soaked nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-soaked nasal packing (1 μg kg−1)
Trial: 33709192
Drug: Dexmedetomidine-soaked nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-soaked nasal packing (2 μg kg−1)
Trial: 33709192
Drug: Dexmedetomidine-soaked nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-soaked nasal packing (4 μg kg−1)
Trial: 36327043
Drug: SC‐R group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC‐R group (n=29) - 24 weeks of no cost Nicotine Replacement Treatment (NRT)
Trial: 36327043
Drug: SC + group (n=32)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC + group (n=32) - 24 weeks of no cost NRT plus two initial individual counselling sessions of motivational interviewing and weekly psychosocial group support for 24 weeks
Trial: 32109729
Drug: Skills preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skills preparation group
Trial: 32109729
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) group
Trial: 33831949
Drug: Antioxidant cocktail
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant cocktail (741 mg/d polyphenols, 2.1 g/d omega-3 fatty acids, 168 mg/d vitamin E, and 80 μg/d selenium)
Trial: 34791283
Drug: PP6M (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP6M (700 or 1000 mg eq.)
Trial: 34791283
Drug: PP3M (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP3M (350 or 525 mg eq.)
Trial: 32004582
Drug: Ultrahypofractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrahypofractionated radiation therapy (UHF) - 7 × 6.1 Gy, 2.5 weeks
Trial: 32004582
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated radiation therapy (CF) - 39 × 2.0 Gy, 8 weeks
Trial: 34554831
Drug: Acid-oxidising solution
RxNorm normalized name: salicylic acid / zinc oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-oxidising solution (AOS)
Trial: 32217557
Drug: SFX-01 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFX-01 (300 mg)
Trial: 35963416
Drug: R. damascena
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R. damascena and brown sugar syrup (0.1 g R. damascena petals mixed with 0.85 g brown sugar per 1 mL)
Trial: 35963416
Drug: R. damascena
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R. damascena and brown sugar syrup
Trial: 36151947
Drug: Needle flexor
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle flexor tendon tenotomy treatment
Trial: 36151947
Drug: Standard nonsurgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nonsurgical treatment alone
Trial: 32493720
Drug: HIV Env
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV Env subunit vaccine
Trial: 38529674
Drug: Deucravacitinib 6
RxNorm normalized name: deucravacitinib 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 6 mg QD
Trial: 32713104
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (HDDT) with rabeprazole 20 mg q.i.d. and amoxicillin 1 g q.i.d. for 14 days
Trial: 32713104
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (STT) with rabeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. for 14 days
Trial: 32246662
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem ointment
Trial: 35020928
Drug: Concurrent viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent viral features and radiographic pneumonia
Trial: 33289822
Drug: Co-trimoxazole (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (960 mg orally twice daily)
Trial: 34228547
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic agents
Trial: 33400412
Drug: VP-102 (0.7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-102 (0.7% w/v cantharidin) applied topically every 21 days for a maximum of 4 treatments.
Trial: 36316921
Drug: Levocarnitine oral
RxNorm normalized name: levocarnitine Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine oral solution
Trial: 32234700
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) app used for 6 weeks
Trial: 35020023
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (EACA) 20 ml of 5% solution
Trial: 35020023
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control) 20 ml
Trial: 33757437
Drug: Cinacalcet alongside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet alongside standard therapy
Trial: 33534264
Drug: Physostigmine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (0.02 mg/kg bolus followed by 0.01 mg/kg/hour for 24 hours)
Trial: 32535711
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2) plus Oxaliplatin (100 mg/m2) every 2 weeks